The number of IBD trials initiated per year grows every year, meaning competition for sites and patients alike. To make sure one of our longtime clients’ IBD studies stood out, we drew on our database of more than 3,900 sites in 40+ countries to find the geo-mix that worked for them—and fast. (And they’re not our only repeat clients: about 95% of our business is repeat and referral.)
To help engage sites for an IBD study in an increasingly competitive landscape, we put together a 3-step early engagement campaign, including investigator letters, 1-to-1 calls, and webinars. Within four weeks, we’d collected 170 CDAs and 150 completed e-questionnaires from 20 countries. Building great relationships isn’t easy, but at PSI, we think it’s worth it.
With the combined efforts of our feasibility, site identification, and startup teams, we were able to complete enrollment two months ahead of schedule in a highly competitive indication—and with 40 more subjects randomized than planned. In today’s crowded IBD clinical trials landscape, surprise yourself. Contact us to learn how PSI CRO can deliver your next IBD trial on time.